@borano
Review of Phase Four of the National Bowel Cancer Screening Program:
"In any decision to transition to a new test type, it is important that the test is approved by the
Therapeutic Goods Administration (as per the guidance in the NBCSP Quality Framework) and a
cost-effectiveness analysis is performed using reliable estimates of test sensitivity and specificity,
as compared with the current iFOBT."
- Forums
- ASX - By Stock
- Sept '21 Deloitte's review of the National Bowel Cancer Screening Program
RHY
rhythm biosciences limited
Add to My Watchlist
6.56%
!
5.7¢

@boranoReview of Phase Four of the National Bowel Cancer...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
5.7¢ |
Change
-0.004(6.56%) |
Mkt cap ! $16.19M |
Open | High | Low | Value | Volume |
6.2¢ | 6.2¢ | 5.7¢ | $8.806K | 150.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 37568 | 5.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 73671 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 37568 | 0.056 |
1 | 9734 | 0.055 |
3 | 119604 | 0.052 |
4 | 175097 | 0.051 |
5 | 612611 | 0.050 |
Price($) | Vol. | No. |
---|---|---|
0.057 | 73671 | 1 |
0.059 | 57478 | 2 |
0.060 | 44654 | 1 |
0.061 | 61771 | 1 |
0.063 | 37527 | 1 |
Last trade - 15.06pm 15/07/2025 (20 minute delay) ? |
Featured News
RHY (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online